Dr. Bugsu Ovunc, M.D, PHD
Pediatric Pulmonology (Pediatric Pulmonology Physician)
23600 Telo Ave Ste 130
Torrance, CA 90505
Who else practices at this address →
Los Angeles County includes primary care (7% of residents) and mental health (13% of residents) shortage areas. About shortage areas
At a glance
- Years since graduation
- 19
- In the NPI registry since
- 2011
Licensed in California since 2019, according to the Medical Board of California. We show license dates only for the states that publish them in bulk; see which states do. For other states, check the state medical board.
The NPI date is when this clinician registered for a National Provider Identifier, the billing number used on health claims. It is not a license, graduation or board-certification date. What an NPI is
Education and training
- 2011Registered with an NPI (national billing number; not a license date)
Medicare’s Care Compare data doesn’t list this clinician’s medical school. Undergraduate school, residency, fellowship, licensing exams and board certification aren’t in public federal data. Board certification can be confirmed with the certifying board (ABMS member boards for MDs, AOA boards for DOs).
Specialties and state licenses
-
Pediatric Pulmonology Physician primary
CA license A160694 (first issued 2019; current) · MA license 258379 · NH license 18129
As reported to the NPI registry. To confirm a license is current, check the state medical board.
Where they work
Medical groups
- Modena Allergy and Asthma Inc. (26 clinicians)
Hospitals this clinician lists with Medicare, and groups they bill Medicare through (Care Compare). Affiliation doesn’t mean they see patients at every location.
Payments from drug and device companies
In 2025, 16 companies reported 52 payments worth $1,322 in total to this clinician.
| Amgen Inc. | $278 |
|---|---|
| Genzyme Corporation | $205 |
| AstraZeneca Pharmaceuticals LP | $203 |
| Blueprint Medicines Corporation | $99.58 |
| GlaxoSmithKline, LLC. | $95.39 |
| Regeneron Healthcare Solutions, Inc. | $78.95 |
| Genentech USA, Inc. | $58.72 |
| Novartis Pharmaceuticals Corporation | $58.04 |
| Food and Beverage | $1,321 |
|---|
From CMS Open Payments. A payment is not evidence of wrongdoing; many are for consulting, teaching or meals. Clinicians can review and dispute their records with CMS.
Industry-funded research
Named as a principal investigator on 3 industry-funded studies in 2025, from 2 companies. The companies reported $104,148 in research payments for these studies, mostly to the institutions running them.
- A randomized,double blind,multicenter,parallel group,phase IIIb 52 week study evaluating the efficacy and safety of PT027 compared with PT007 administered as needed in participants 12 to under 18 years of age with as…
AstraZeneca UK Limited - Study of Lunsekimig (SAR443765) Compared With Placebo in Adults With High-risk Asthma
Sanofi US Services Inc. · Active, not recruiting · NCT06676319 - Multicentre,Randomised,Double blind,Parallel Group,Placebo controlled,Time to first Asthma Exacerbation Phase tree Efficacy and Safety Study of Benralizumab in Paediatric Patients with Severe Eosinophilic Asthma Dominika
AstraZeneca UK Limited
From CMS Open Payments research payments, where companies name up to five principal investigators per payment. Research payments usually go to hospitals, universities and research sites, not to the investigator personally. A payment is not evidence of wrongdoing.